A review of the recent evidence suggests that GLP-1 drugs, such as semaglutide, could protect brain health and cognitive ...

Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” ...

Fewer than 20% of large employers are covering GLP-1 weight loss drugs like Ozempic, a new KFF analysis shows.

The popularity of GLP-1 weight loss drugs has soared, which had created a shortage among many of the drugs, including Eli ...

The FDA said it will reconsider the removal of Eli Lilly’s GLP-1 drug tirzepatide from its official shortage list, after a ...

Research highlights how GLP-1 receptor agonists may improve brain health by targeting the neurovascular unit, linking ...

According to the Congressional Budget Office, the average 2034 per-user effect could be $650 in savings and $4,300 in costs ...

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

《共识》指出，在2型糖尿病（T2DM）和肥胖症的治疗中，胰高糖素样肽1 受体激动剂（GLP-1RA）类药物因其在控制血糖和减轻体重方面的显著效果，受到越来越多的关注。近期，国家药品监督管理局批准了多个用于体重管理的 GLP-1RA ...

WW International, known as WeightWatchers, saw its stock soar on new of its new compounded GLP-1 offering. But analysts say ...

Mounjaro and Zepbound are now out of shortage. This should be good news—but because so many patients are taking compounded ...

丹麦生物技术公司Zealand Pharma的减肥产品Petrelintide是一种长效淀粉酶类似物，与传统的GLP-1治疗方法相比，Zealand肥胖注射剂Petrelintide的减肥质量更高——使用者的肌肉损失减少，副作用也更少。